Business
Camurus appoints Jane Buus Laursen as Chief Corporate Development Officer
Camurus appoints Jane Buus Laursen as Chief Corporate Development
About this update from Camurus Ab
Lund, Sweden -- 17 February 2026 -- Camurus (NASDAQ STO: CAMX) today announced that Jane Buus Laursen has been appointed as Camurus' Chief Corporate Development Officer (CCDO) and member of the executive management team, effective 23 March, 2026 . Jane brings more than 20 years of experience from senior positions at Novo Nordisk and AstraZeneca within Business and Corporate Development, with a strong track record of driving strategic licensing and M&A transactions, integration processes and alliance management. Most recently, she had the position as Corporate VP in Global Business Development at Novo Nordisk . Jane holds a PhD in Organic & Medicinal chemistry from the Technical University of Denmark (DTU) and the University of Kansas , US, and has a background as senior scientist. "We are pleased to welcome Jane Buus Laursen to Camurus as Chief Corporate Development Officer. Jane will have a central role in the company with responsibility for strategic development towards new growth targets, expansion and long-term value creation, together with the executive management", says Fredrik Tiberg , Camurus ' President and CEO. "Jane offers significant experience from senior positions at leading pharmaceutical companies and joins Camurus during ongoing growth and expansion." "I am excited to join Camurus at a pivotal point of its growth, with strong momentum and opportunity ahead. I am highly motivated by the strong science-driven and agile culture and clear focus on improving patients' lives. I look forward to working closely with Fredrik, the executive management, and colleagues across the organization, to develop and implement Camurus' strategic priorities for long-term growth", says Jane Buus Laursen . About Camurus Camurus is an international, science-led biopharmaceutical company committed to developing and commercializing innovative, long-acting medicines for improving the lives of patients with severe and chronic diseases. New drug products with best-in-class potential are conceived based on the company's proprietary FluidCrystal ® technology and its extensive R&D expertise. The R&D pipeline includes products for the treatment of dependence, pain, cancer, and endocrine diseases. Camurus has operations across Europe , the US, and Australia , with headquarters in Lund, Sweden . The company's shares are listed on Nasdaq Stockholm under the ticker CAMX. For more information, visit www.camurus.com and LinkedIn . For more information Fredrik Tiberg , President & CEO Tel. +46 (0)46 286 46 92 [email protected] Fredrik Joabsson, Chief Business Development Officer Tel. +46 (0)70 776 17 37 [email protected] This information was submitted for publication at 8:00 am CET on 17 February 2026 . https://news.cision.com/camurus-ab/r/camurus-appoints-jane-buus-laursen-as-chief-corporate-development-officer,c4306725 https://mb.cision.com/Main/13456/4306725/3936612.pdf (c) 2026 Cision. All rights reserved., source Press Releases - English